Skip to main content

Critical Care Reviews Newsletter

Newsletter 482  |  March 8th 2021


Welcome to the 482nd Critical Care Reviews Newsletter, bringing you the best critical care research and open access articles from across the medical literature over the past seven days.

The highlights of this week's edition are two randomised controlled liver trials, investigating terlipressin plus albumin for the treatment of type 1 hepatorenal syndrome & albumin infusions in hospitalized patients with cirrhosis, respectively, as well as a further two RCTs examining tocilizumab in COVID-19; systematic reviews and meta analyses on N-acetylcysteine in non-acetaminophen-related acute liver failure & the timing of renal replacement therapy for patients with acute kidney injury; and observational studies on long term outcomes of participants in the PARAMEDIC2 randomised trial of adrenaline in out-of-hospital cardiac arrest & recovery of consciousness and functional outcome in moderate and severe traumatic brain injury.

There is also a guideline on the universal definition and classification of heart failure; narrative reviews on ten golden rules to individualize mechanical ventilation in ARDS & a two part series on the pulmonary artery catheter; commentaries on COVID-19 research in critical care & rationing guidelines during a pandemic; as well as correspondence on tocilizumab in patients hospitalized with Covid-19 pneumonia.

If you only have time to read one article this week, try this fascinating one on the potential future of the COVID-19 pandemic. There is also a new intensive care medicine journal to start following - The Journal of Intensive Medicine.


I hope you find this newsletter useful.

Until next week




Supported by the Health Research Board